SEC Filing Summary: Social Capital Suvretta Holdings Corp. III
Business Context and Reporting Period
This Form 8-K, dated July 2, 2021, reports the consummation of the initial public offering (IPO) by Social Capital Suvretta Holdings Corp. III (trading symbol: DNAC). The registrant is a Cayman Islands-based special purpose acquisition company (SPAC) and an emerging growth company. While the metadata references "PROKIDNEY CORP.", the filing text identifies the registrant as Social Capital Suvretta Holdings Corp. III; ProKidney Corp. is not mentioned in the provided text.
Key Financial Metrics
- Gross Proceeds from IPO: $250,000,000 from the sale of 25,000,000 Class A ordinary shares at $10.00 per share.
- Over-Allotment Exercise: Included 3,000,000 shares issued via partial exercise of the underwriters' over-allotment option.
- Private Placement Proceeds: $6,400,000 from the sale of 640,000 shares to the sponsor, SCS Sponsor III LLC, at $10.00 per share.
- Total Trust Account Funding: $250,000,000 placed in a U.S.-based trust account at JP Morgan Chase Bank, N.A.
- Revenue, Profit, and Cash Flow: The filing text does not provide operating revenue, net profit, or operating cash flow figures, as the company is a pre-operational SPAC.
- Debt and Liquidity: The filing text does not explicitly state debt levels or liquidity ratios beyond the trust account balance.
Material Changes
The primary material change is the transition from a private entity to a publicly traded company on the Nasdaq Capital Market. The company's balance sheet was updated to reflect the receipt of $256,400,000 in total gross proceeds (IPO and private placement combined), with $250,000,000 restricted in the trust account.
Outlook, Risks, and Management Commentary
The filing confirms the closing of the IPO and the establishment of the trust account required for future business combinations. No specific guidance, risk factors, or management commentary regarding future targets or operational outlook is included in this specific text excerpt. The filing notes the inclusion of an audited balance sheet as of July 2, 2021, as Exhibit 99.1.
Investor Verification Checklist
- Verify the identity of the registrant (Social Capital Suvretta Holdings Corp. III) versus the metadata label (PROKIDNEY CORP.) to ensure correct entity analysis.
- Review Exhibit 99.1 (Audited Balance Sheet) for details on underwriting discounts, offering expenses, and working capital outside the trust account.
- Confirm the terms of the over-allotment option and any remaining unexercised portion.
- Examine the trust agreement to understand withdrawal conditions and interest accrual on the $250,000,000 held in trust.